Done: Who It's Best For (Ideal Patient Profile, Cost, and Clinical Fit)

What Done Actually Is

Done operates as a subscription telehealth service connecting patients with nurse practitioners and physicians who diagnose and treat ADHD via video appointments. The platform uses a screening questionnaire based on the Adult ADHD Self-Report Scale (ASRS-v1.1), a validated 6-item tool developed by the World Health Organization [1]. After screening, patients schedule a synchronous video evaluation with a prescriber.

The service launched in 2020 during the COVID-19 public health emergency, which temporarily relaxed DEA requirements for prescribing controlled substances via telehealth. Since the permanent reinstatement of in-person requirements under the DEA's 2025 telemedicine rule, Done has adapted its protocols to comply with audio-video evaluation standards for Schedule II prescriptions [2].

Done is not a diagnostic testing center. It does not offer neuropsychological evaluation, continuous performance testing (CPT), or psychotherapy. Patients who need those services require referral elsewhere.

The Ideal Patient Profile for Done

The adult most likely to benefit from Done fits a specific clinical and logistical profile. This person is between 25 and 45, employed, and has long suspected they have ADHD but never received a formal evaluation. They live in a region with a 3- to 6-month wait for outpatient psychiatry. A 2022 JAMA Network Open study found that the median wait time for a new outpatient psychiatry appointment in the United States was 67 days, with some markets exceeding 6 months [3].

The ideal Done patient also meets these criteria:

• No active substance use disorder. The American Academy of Addiction Psychiatry recommends against prescribing stimulants to patients with untreated or active substance use disorders [4]. Done's intake screens for this, though the depth of screening varies by provider.
• No complex comorbidity requiring integrated care. Patients with bipolar disorder, active psychosis, or severe anxiety may need stabilization before stimulant initiation. The American Psychiatric Association's 2019 practice guidelines emphasize that ADHD medications should be prescribed only after mood destabilization risks are assessed [5].
• Comfort with a subscription model. Done charges monthly regardless of whether the patient needs a medication adjustment. Patients who prefer fee-for-service or insurance-based care are not well served.
• Prior positive response to stimulant medication (for returning patients). Adults who previously took methylphenidate or amphetamine salts and lost access due to a provider move or insurance change find Done's quick onboarding useful.

The patient who does not fit: someone with untreated bipolar II, active alcohol dependence, a history of stimulant misuse, or a need for combined psychotherapy and pharmacotherapy.

Is Done Legitimate?

Done is a registered medical practice operating under state medical board oversight. Its providers hold active DEA registrations and state licenses. The platform is not a pharmacy; prescriptions are sent to the patient's pharmacy of choice.

Legitimacy concerns intensified in 2022 when the Wall Street Journal reported that Done and competitor Cerebral faced DOJ scrutiny over prescribing volume [6]. The investigation centered on whether certain providers were prescribing stimulants after inadequate evaluations. No criminal charges have been filed against Done as a corporate entity, though the reporting prompted internal policy changes including mandatory 30-minute minimum evaluations and structured documentation requirements.

The broader clinical question is not whether Done is "legal" but whether its evaluation depth matches the standard of care. The American Professional Society of ADHD and Related Disorders (APSARD) recommends a comprehensive diagnostic interview lasting 45 to 90 minutes for initial ADHD evaluation [7]. Done's reported 30-minute initial visits fall below this benchmark.

A 2023 JAMA Internal Medicine study analyzing telehealth ADHD prescribing patterns found that patients receiving stimulant prescriptions via telehealth platforms were less likely to receive follow-up behavioral interventions compared to those seen in traditional settings (18.2% vs. 34.7%, P<0.001) [8]. This gap matters clinically because the NIMH Multimodal Treatment Study of ADHD (MTA, N=579) demonstrated that combined pharmacotherapy and behavioral treatment produced superior long-term functional outcomes compared to medication alone [9].

What Done Prescribes

Done providers prescribe across the standard ADHD pharmacopeia:

First-line stimulants:

• Mixed amphetamine salts (Adderall, Adderall XR): typical starting dose 10 to 20 mg/day
• Lisdexamfetamine (Vyvanse): typical starting dose 30 mg/day
• Methylphenidate (Concerta, Ritalin): typical starting dose 18 to 36 mg/day extended-release

Non-stimulant alternatives:

• Atomoxetine (Strattera): 40 to 80 mg/day target dose
• Bupropion (Wellbutrin XL): 150 to 300 mg/day, used off-label for ADHD with comorbid depression
• Viloxazine (Qelbree): FDA-approved for adult ADHD in 2023 at 200 to 600 mg/day [10]

According to American Academy of Pediatrics and adult ADHD guidelines, stimulants remain first-line for uncomplicated adult ADHD, with response rates of 70 to 80% compared to 50 to 60% for non-stimulants [11]. Done's prescribing appears to follow this evidence hierarchy, though individual provider variability exists.

Schedule II prescriptions (all stimulants) require monthly video follow-up under current DEA regulations. Non-stimulants like atomoxetine can be prescribed with longer intervals between visits.

How Much Done Costs

Done's pricing as of early 2026:

• Initial evaluation: $199 (included in first month's subscription)
• Monthly membership: $199/month for standard tier; $299/month for "priority" tier with faster scheduling
• Medication cost: Not included. Patients fill prescriptions at retail pharmacies. Generic amphetamine salts cost approximately $30, $60/month with GoodRx coupons; brand-name Vyvanse runs $350, $400/month without insurance.

Over 12 months, a Done patient on generic stimulants pays approximately $2,748, $3,948 total (subscription plus medication). For comparison, a patient with commercial insurance seeing an in-network psychiatrist pays roughly $600, $1,200/year in copays for quarterly visits plus $120, $720/year in medication copays, depending on formulary tier [12].

Done's value proposition depends entirely on access. For the patient facing a 4-month wait for a psychiatrist, paying $199/month to start treatment within a week may be worth the premium. For someone with functioning insurance and available providers, the math does not favor Done.

Done vs. Alternatives

Several telehealth ADHD platforms compete directly with Done:

Cerebral ($85, $325/month): Offers therapy bundled with medication management. Better fit for patients wanting integrated behavioral support. Faced similar DOJ scrutiny in 2022.

ADHD Online ($199 one-time assessment, then per-visit): Uses a more comprehensive psychometric battery including the DIVA-5 structured diagnostic interview. Better fit for patients who want formal diagnostic certainty before starting medication.

Talkiatry (insurance-accepted): Full-scope telepsychiatry accepting major insurance plans. Wait times are longer (2 to 4 weeks) but costs are dramatically lower for insured patients.

Traditional psychiatry: Remains the gold standard per APSARD guidelines [7]. Provides neuropsychological testing access, integrated therapy referrals, and continuity of care that subscription platforms cannot replicate.

Done's competitive position is speed and simplicity. Patients who prioritize fast access to medication management over comprehensive evaluation or integrated therapy are its core market. A 2024 survey in the Journal of Attention Disorders (N=412) found that 62% of adults seeking telehealth ADHD care cited "wait time frustration" as their primary motivator, while only 23% cited cost [13].

Clinical Risks and Limitations

Stimulant medications carry cardiovascular risks. The FDA requires black-box monitoring for sudden death in patients with structural cardiac abnormalities [14]. Done's intake asks about cardiac history, but the absence of physical examination means subclinical conditions (hypertrophic cardiomyopathy, undiagnosed arrhythmias) could be missed.

The APSARD 2024 consensus statement recommends baseline EKG for patients over 40, those with family history of sudden cardiac death, or those with cardiac symptoms before stimulant initiation [7]. Whether Done consistently implements this recommendation is unclear from publicly available information.

Diversion risk is the other concern. A 2021 study in Drug and Alcohol Dependence found that 16.6% of college-age adults with stimulant prescriptions reported giving or selling medication to others [15]. Telehealth platforms with brief evaluations may have reduced ability to detect diversion intent compared to longitudinal in-person relationships.

Dr. David Goodman, director of the Adult Attention Deficit Disorder Center of Maryland and assistant professor at Johns Hopkins, stated in a 2023 interview with NPR: "The 30-minute telehealth visit cannot replicate the depth of a comprehensive ADHD evaluation. It can identify obvious cases, but subtle presentations and comorbid conditions require more time and clinical sophistication."

The Endocrine Society's guidelines on stimulant effects note that amphetamines can suppress appetite and reduce sleep quality, potentially affecting cortisol rhythms and metabolic health in long-term use [16]. Patients on Done should ensure their provider monitors weight, blood pressure, and sleep patterns at each monthly check-in.

What Done Reviews Actually Say

Trustpilot reviews of Done (as of early 2026) average 3.2/5 across approximately 2,800 reviews. Common positive themes include fast onboarding, responsive scheduling, and helpful individual providers. Common negative themes include difficulty canceling subscriptions, inconsistency between providers, and pharmacy coordination problems.

The Better Business Bureau shows a B+ rating with 147 complaints filed in the past 12 months, primarily regarding billing disputes and prescription delays.

"I was diagnosed within a week and started medication that changed my work performance," noted one representative positive review. "But when my provider left the platform, I had to re-do my entire intake with someone new who wanted to change my stable regimen." This experience highlights a structural weakness of platform-based care: provider turnover disrupts therapeutic continuity.

Who Should Look Elsewhere

Patients in these categories should not use Done as their primary ADHD provider:

• Adolescents under 18: Done does not treat minors. Pediatric ADHD requires different evaluation standards per AAP guidelines [17].
• Patients with active substance use disorders: Stimulant prescribing in this population requires addiction medicine expertise and close monitoring beyond monthly video visits.
• Patients needing formal neuropsychological testing: Done does not offer CPT, DIVA-5, or IQ-discrepancy analysis. These tools matter for disability accommodations, forensic evaluations, and complex differential diagnosis.
• Patients with bipolar disorder or psychotic features: Stimulants can trigger mania or psychosis. These patients need mood stabilization first, ideally under in-person psychiatric supervision.

The baseline heart rate and blood pressure measurement recommended before stimulant initiation requires either a home blood pressure cuff or a single in-person vital sign check. Done reportedly instructs patients to obtain home readings, though compliance verification is limited.